Growing use of complementary and alternative supplements (CAS) is of concern because of the potential for herb-drug interaction among cardiovascular patients. Literary searches were conducted on PubMed to identify reports of extent and purpose of CAS use, disclosure of use by patients, physician knowledge, and possible drug-CAS interactions for cardiovascular patients. Additional published studies were located through the Web sites of various organizations. Further searches of case reports, case series, controlled trials, and laboratory evidence were performed for each of the top 10 CAS and their possible cardiovascular drug interactions. More research is needed to understand supplement-drug interactions, particularly in terms of how this potentially affects patients taking cardiovascular drugs. With this lack of research and clarity on supplement-dug interactions and the underreporting of CAS use by many patients, physician education is also in need of improvement.
Method
In January and February of 2006 we conducted literary searches to identify reports of the extent and purpose of CAM and CAS use, patients' report of use of CAS to health care providers, physician knowledge of CAS risks, and the possibility of drug-CAS interactions in cardiovascular patients. Data sources included Ovid and PubMed websites. The key MeSH terms used were "complementary therapies," "dietary supplements," "vitamins," "heart failure," "cardiovascular disease," "physicians," and "herb-drug interactions." Subheadings used include "therapeutic use," "utilization," "statistics and numerical data," "education," "trends," "economics," and "medical history taking." To identify additional published studies, we searched the NIH, NCCAM, FDA, CDC, and GAO Web sites. The bibliographies of electronically indexed articles were searched for additional relevant studies. Excluded were data from commercial Web sites, studies with commercial aims, and studies with the central goal of proving or disproving the claimed health benefits of CAM.
Data were abstracted from the included studies in the areas of (a) use of CAS and demographics of those who use CAS and (b) physicians' knowledge of CAS use and possible drug interactions. The top 10 most used CAS, as determined by the NCCAM/CDC report (Barnes et al., 2004; NCCAM, 2006) , are listed in Table 1 . This report estimated CAM use among U.S. adults, using data from the 2002 National Health Interview Survey, conducted by the CDC's National Center for Health Statistics. Data were based on 31,044 interviews of adults 18 years and older (Barnes et al., 2004) . Data were also collected on the intended use of the top 10 used CAS supplements as well as documented and possible drug interactions. These interactions were then correlated with a list of commonly used cardiovascular drugs obtained from the American Heart Association Web site (American Heart Association, 2006a) .
To further investigate and establish the available research on CAS-drug interactions pertaining to cardiovascular health, we performed additional searches of PubMed for literature on drug interactions with the top 10 used CAS as determined by the NCCAM/CDC study (Barnes et al., 2004; NCCAM, 2006) . We performed 10 additional individualized searches using the names of the top 10 used CAS and "drug interaction" as key search terms. We limited these 10 searches to case reports, case series, controlled trials, or laboratory evidence that directly touched on the topic of cardiovascular health or cardiovascular medications.
Results

Who Uses CAS?
To assess the magnitude of potential risks of negative drug-CAS interaction, it is important to understand who is taking CAS and their motivation for doing so. Although CAM use spans the whole population, groups most likely to use CAM include women, people with higher education, people who have been hospitalized in the past year, and former smokers (Barnes et al., 2004; NCCAM, 2006) . One fifth of the people surveyed by NCCAM/CDC reported using natural products in the preceding year (Barnes et al., 2004) . Several studies also suggest that CAM use is more prevalent in older adults. One study focused on CAM use in an elderly urban population showed that as many as 58% of survey respondents had used some form of CAM (Cherniack, Senzel, & Pan, 2001) . In a study examining preoperative use of CAS, the average age of users was 54 years (Grauer, Thomas, Tronson, Heard, & Diacon, 2004) .
Studies show that people who have been hospitalized in the last year also are more likely to use CAM (Barnes et al., 2004) . This combined with the fact that rates of CAM use are exceptionally high among people with chronic and life-threatening diseases should be an indicator that discussions of CAS use must become an active part of patient-physician interactions (Barnes et al., 2004; . Over half of adult CAM users claimed their main reason for using CAM treatments was that they believed that, combined with conventional treatments, CAM would improve their health (Barnes et al., 2004) . This suggests that the majority of people who are taking CAS will continue or begin conventional treatments while maintaining their CAS intake. Both individuals who have lost faith in conventional treatments and those who underestimate the pharmacological effects of natural supplements would be prone to omitting their use of CAS in discussions with their physicians.
Similar figures of CAS and CAM use have been found among populations with cardiovascular disease. A survey of 252 chronic heart failure patients showed that one third of them were taking CAS, several of which may interact with heart failure medications. Eighty-two percent of the patients who used CAS were taking them for cardiac-related problems (Zick, Blume, & Aaronson, 2005) . Another survey of 107 patients with cardiovascular disease found that 65% of the CAM users similarly cited their cardiovascular disease as the reason for CAM use (Wood et al., 2003) .
Patient underreporting of CAM use to health care providers. A number of studies have documented underreporting of CAM by patients. One study found that 58% of respondents used 129 CAM therapies in the preceding month. Of these 129 CAM therapies, only 28% were recorded in the patients' charts (Cockayne, Duguid, & Shenfield, 2005) . Giveon, Liberman, Klang, & Kahan (2004) state that among CAM users close to 40% of them never reported their use to their physicians. In a comprehensive literature search, the proportion of CAM users not reporting their use was as high as 77% (Robinson & McGrail, 2004) . The same study revealed that the top reasons for not disclosing use were expectation of a negative reaction from their health care provider, the thought that there was no need to report CAM use, and the fact that they were never asked about CAM by their health care provider (Robinson & McGrail, 2004) . Underreporting occurs across patient groups. For example, in a study of CAM use by migraine patients, approximately 61% of CAM users had not reported use to their medical doctor (Rossi et al., 2005) . The underreporting of CAS use is particularly worrisome. As patients' use of CAS increases, there is a need to improve the communication between patients and health care providers. Patients do not appear to recognize the importance of reporting CAS use to their physicians. In a study of CAS use in preoperative patients, only 27.8% of CAS users reported their use to the admitting physician or surgeon (Grauer et al., 2004) . This is significant given that many commonly used CAS affect blood clotting. For example, St. Johns wort, glucosamine, ginseng, garlic, ginkgo biloba, and coenzyme Q10 act as either blood thinners or anticoagulants (U.S. GAO, 2001) . Although patients fail to volunteer information about CAS use, physicians also neglect to discuss CAS use with their patients. One study of a family medicine practice showed CAS use was not discussed with 84% of patients in their most recent clinic visit and 59% had never been asked about CAS use by their physician (Grant, Barney, Wagner, Moseley, & Dianati, 2000) . Given the reluctance of patients to disclose CAS use, proactive inquiry about CAS use becomes an important part of patient history taking and discussion of individual health care. One article specifically addressing CAM use in cancer patients found that at the initial standard history taking and physical examination 7% of participants were found to be using CAM. When the remaining patients were asked directed questions about CAM use, the percentage of those using CAM increased to 40%. Of the patients who were using CAM, 84% of them were identified only through directed questioning (Metz, Jones, Devine, Hahn, & Glatstein, 2001) . In a study specifically examining CAM use by cardiovascular patients, one survey showed that 40% of 107 cardiovascular disease patients were CAS users (Wood et al., 2003) . An in-depth review of the use of naturoceutical agents (CAS) in the management of cardiovascular disease in 2002 suggested that the lack of clinical studies and scientific data leaves a gap in health care providers' knowledge of the effects of CAS use (Hermann, 2002) .
Physicians Underestimate the Risk
Discrepancies in patient medical history and actual CAS use may result in part from physicians and patients underestimating the risks of CAS and conventional interactions. A survey of 740 patients at family medicine practices showed that 56.2% of respondents believed that natural drugs do not cause side effects (Giveon et al., 2004) . The fact that patients do not always recognize the risks of CAS is less surprising than the fact that physicians also fail to recognize these risks. A separate survey by the same researchers showed that of 150 physicians surveyed 51% believed that herbal remedies have no, or mild, side effects. In addition, 70% of the physicians reported having little or no knowledge of CAS (Giveon, Liberman, Klang, & Kahan, 2003) . Another study specifically looking at the awareness levels among physicians of the risk of drug-CAS interactions showed that even when physicians asked patients about CAS use they did not look up the CAS in a reference text to assess the risk of drug interactions. The survey also asked physicians to match 10 herbs to 10 side effects. The mean number that answered correctly was 1.32, further revealing the lack of physician knowledge concerning CAS interactions (Silverstein & Spiegel, 2001) . However, we can hope that physicians have become more knowledgeable since the publication of these studies and that the continued discussion of CAS use will continue to spread knowledge.
Possible Drug-CAS Interactions
Several articles addressed the possibility of negative interactions between common cardiovascular medications and CAS (Chagan, Ioselovich, Asherova, & Cheng, 2002; Hermann, 2002; U.S. GAO, 2001; Wood et al., 2003; Zick et al., 2005) . However, only one article, a literature review, addressed the issue that several CAS with properties that could promote cardiovascular health might also present the possibility of negative drug interactions (Miller, Liebowitz, & Newby, 2004) . In this study, five CAS with the properties that could promote cardiovascular health were examined for possible drug interactions. In addition, the five CAS examined often came with claims of cardiovascular health benefits. However, none of them are found in the top 10 used CAS (NCCAM, 2006) . To obtain a more comprehensive look at the effects that CAS use may have on cardiovascular health and the possibility for drug-CAS interaction, we compiled data on the top 10 used CAS, their suggested uses, and their potential for interactions with commonly used cardiovascular drugs. As part of this process, we conducted further literature research on each of the top 10 CAS used in the United States as reported by the NCCAM (2006), looking for their uses and possible or reported drug interactions.
Examining the top 10 used CAS with the potential for interaction with cardiac-related medication, we conclude that cardiovascular patients who use common CAS could be at risk of a drug-CAS interaction. Potential interactions for the top 10 used CAS were collected from the NIH Office of Dietary Supplements Web page (NIH Office of Dietary Supplements, 2006a). Because of the nature of CAS use and the lack of research on their effectiveness and possible side effects, potential interactions are often assumed based on the nature of the supplement and the drug independent of each other. Possible interaction warnings found on the NIH Office of Dietary Supplements often read similar to the example cited here for ginkgo biloba.
There are some data to suggest that ginkgo can increase bleeding risk, so people who take anticoagulant drugs, have bleeding disorders, or have scheduled surgery or dental procedures should use caution and talk to a health care provider if using ginkgo. (NIH Office of Dietary Supplements, 2006b, para. 11) Articles found in our search for the top 10 used CAS and their possible drug interactions revealed limited research. For all 10 searches there were seven case reports found, five randomized controlled trials, and six other articles that were either retroactive studies or comparative studies. Case reports on possible CAS interactions were found for ginger, ginkgo biloba, ginseng, glucosamine, omega-3 fatty acids, and soy (Cambria-Kiely, 2002; Jayasekera, Moghal, Kashif, & Karalliedde, 2005; Kruth, Brosi, Fux, Morike, & Gleiter, 2004; Lesho, Saullo, & Udvari-Nagy, 2004; McClaskey & Michalets, 2007; Rozenfeld, Crain, & Callahan, 2004) . Randomized controlled trials were found for garlic and anticoagulation therapy, ginseng and warfarin, ginkgo biloba and coagulation, and ginkgo biloba and warfarin (Candelario-Jalil et al., 2006; Jiang, Blair, & McLachlan, 2006; Jiang et al., 2005; Macan et al., 2006; Wolf, 2006) . Garlic was shown to be safe if carefully monitored, ginseng was shown to significantly increase the clearance/bioavailability of S-warfarin (data that gives cause for further studies), and ginkgo biloba was shown to present no significant health risk in the study group. However, further studies in the elderly were suggested (Candelario-Jalil et al., 2006; Jiang et al., 2005 Jiang et al., , 2006 Macan et al., 2006; Wolf, 2006) .Where some studies and reports found a safety risk and some did not, all found the need for further development and research in the area of CAS-drug interactions (Cambria-Kiely, 2002; Candelario-Jalil et al., 2006; Jayasekera et al., 2005; Jiang et al., 2005 Jiang et al., , 2006 Kruth et al., 2004; Lesho et al., 2004; Macan et al., 2006; McClaskey & Michalets, 2007; Rozenfeld et al., 2004; Wolf, 2006) .
A list of cardiac-related medications that may have interactions with CAS, collated from information provided on the NIH Office of Dietary Supplement Web page, include ace inhibitors, aldostrerone antagonists, antiarrhythmics, anticoagulants, antiplatelets, angiotensin receptor blockers, beta-blockers, blood thinners, diuretics, and digitalis drugs. Garlic, soy, and omega-3 fatty acids are in the top 10 CAS used by U.S. adults according to the NCCAM. Together these three CAS are used by 41% of the adult taking CAS in the United States (National Center of Complementary and Alternative Medicine & National Institute of Health, 2006) . In addition, one survey showed that 40% of 107 cardiovascular disease patients were CAS users (Wood et al., 2003) . Of the top 10 CAS all but one (peppermint) carry the risk of interaction with commonly used cardiovascular medications.
Discussion
CAS are used by all population subgroups and for a wide range of health issues. Patients with cardiovascular health issues are at a particularly high risk for adverse events of CAS use. With 9 of the top 10 most used CAS having the potential for negative interaction with one or more prescription drugs used in the treatment of cardiovascular health problems, there is valid reason for concern (Barnes et al., 2004; Table 1 ). The increased potential for negative drug-CAS interaction, coupled with underreporting of CAS use, exposes many patients to risk of adverse events. It is necessary that those involved in the care of cardiovascular patients become educated in this area and in turn educate their patients about CAS-conventional medication interactions.
Although there should be growing concern about the potential risks of negative CAS interactions with cardiovascular medications, few data are available. Several commonly used CAS may interact with drugs including warfarin and digoxin. In addition, many of the CAS with risks of adverse interactions are also separately recommended for improving cardiovascular health. This highlights the importance of health care providers, and cardiologists in particular, learning more about CAS. The potential risks of severe interaction between CAS and prescribed medication for cardiovascular patients highlights the need for further research on concurrent or integrated use of CAM and conventional medicine (Hermann, 2002) . Another review of CAS use in cardiovascular disease concluded that the potential for interaction between commonly used supplements and commonly prescribed medications used in cardiovascular disease is great and advised that more research be conducted (Miller et al., 2004) . Other research highlights potential dangers associated with CAS-conventional medication interactions, specifically with warfarin, and explains why CAS hold the potential for negative interaction for patients being treated for cardiovascular disease (Chagan et al., 2002; Evans, 2000) . Research to date supports the same conclusions: that physician awareness is low, patient underreporting CAS use is high, and clinical research on the effects and interactions of supplements and conventional medicines is insufficient.
Conclusions
There is no doubt that CAM use, and specifically CAS use, is increasing. There exist ample data indicating that the popularity of CAS in health care will continue. What is lacking is the acknowledgement by both patients and physicians that CAS, regardless of FDA labeling, may have both positive and/or negative effects in cardiovascular care. The possibilities of negative drug-CAS interactions create risks to patient health exacerbated by the lack of knowledge and discussion of CAS use. Given the levels of potential interactions between the top 10 used CAS and cardiovascular medications, it is particularly important that cardiologists and other clinicians involved in the care of patients with cardiovascular disease learn more about CAS use. More research is needed to demonstrate the actual risks of drug-CAS interaction, but until research results are available it is the responsibility of health care providers to become informed about CAS to the extent possible. Without appropriate knowledge of CAS use and CAS effects, health care providers in the cardiovascular field cannot provide the most effective and safe care to their patients.
